| Literature DB >> 27574595 |
Sung Yong Cho1, Young Deuk Choi2.
Abstract
PURPOSE: Prostate tumor volume calculated after surgery using pathologic tissue has been shown to be an independent risk factor for biochemical recurrence. Nonetheless, prostate size varies among individuals, regardless of the presence or absence of cancer. We assumed to be lower margin positive rate in the surgical operation, when the prostate volume is larger and the tumor lesion is same. Thus, we defined the tumor-prostate ratio in the ratio of tumor volume to prostate volume. In order to compensate the prostate tumor volume, the effect of tumor-prostate ratio on biochemical recurrence was examined.Entities:
Keywords: Prostatectomy; Prostatic neoplasms; Risk factors
Year: 2016 PMID: 27574595 PMCID: PMC4999485 DOI: 10.5534/wjmh.2016.34.2.123
Source DB: PubMed Journal: World J Mens Health ISSN: 2287-4208 Impact factor: 5.400
Characteristics of the patients who underwent radical prostatectomy
| Characteristic | No. of patient (%) |
|---|---|
| Age (yr) | |
| <65 | 115 (45.8) |
| ≥65 | 136 (54.2) |
| Prostate volume (mL) | |
| <40 | 156 (62.2) |
| ≥40 | 95 (37.8) |
| Prostate-specific antigen (ng/mL) | |
| <10 | 125 (49.8) |
| ≥10 | 126 (50.2) |
| Gleason score (biopsy) | |
| ≤6 | 128 (51.0) |
| 7 | 77 (30.7) |
| ≥8 | 46 (18.3) |
| Clinical stage | |
| Stage cT1 | 112 (44.6) |
| Stage cT2 | 105 (41.8) |
| Stage cT3 | 34 (13.5) |
| Pathologic stage | |
| Stage pT1 | 1 (0.4) |
| Stage pT2 | 121 (48.2) |
| Stage pT3 | 101 (40.2) |
| Stage pT4 | 28 (11.2) |
| Gleason score | |
| <7 | 89 (35.5) |
| ≥7 | 162 (64.5) |
| Surgical margin invasion | |
| No | 149 (59.4) |
| Yes | 102 (40.6) |
| Capsular invasion | |
| No | 110 (43.8) |
| Yes | 141 (56.2) |
| Seminal vesicle invasion | |
| No | 212 (84.5) |
| Yes | 39 (15.5) |
| Lymph node invasion | |
| No | 242 (96.4) |
| Yes | 9 (3.6) |
| Tumor volume (mL) | |
| <5 | 208 (82.9) |
| ≥5 | 43 (17.1) |
| Tumor density | |
| <10 | 186 (74.1) |
| ≥10 | 65 (25.9) |
| Pathologic stage pT3c | |
| <pT3 | 204 (81.3) |
| ≥pT3c | 47 (18.7) |
| Pathologic stage pT4a | |
| <pT4a | 223 (88.8) |
| ≥pT4a | 28 (11.2) |
| Total | 251 (100.0) |
Univariate analysis of the risk factors for biochemical recurrence
| Risk factor group | 5 years of recurrence-free survival (%) | p-value |
|---|---|---|
| Prostate volume (mL) | 0.305 | |
| <40 | 71.5 | |
| ≥40 | 64.4 | |
| Prostate-specific antigen (ng/mL) | 0.009 | |
| <10 | 85.3 | |
| ≥10 | 62.0 | |
| Gleason score | 0.062 | |
| <7 | 81.1 | |
| ≥7 | 66.8 | |
| Surgical margin invasion | 0.000 | |
| No | 82.4 | |
| Yes | 55.3 | |
| Capsular invasion | 0.009 | |
| No | 76.7 | |
| Yes | 68.1 | |
| Seminal vesicle invasion | 0.225 | |
| No | 72.0 | |
| Yes | 65.8 | |
| Lymph node invasion | 0.008 | |
| No | 72.6 | |
| Yes | 38.9 | |
| Tumor volume (mL) | 0.010 | |
| <5 | 73.4 | |
| ≥5 | 61.3 | |
| Tumor-prostate ratio (%) | 0.007 | |
| <10 | 74.0 | |
| ≥10 | 62.4 | |
| Pathologic stage pT2ca | 0.150 | |
| <pT2c | 59.4 | |
| ≥pT2c | 73.9 | |
| Pathologic stage pT3aa | 0.086 | |
| <pT3a | 73.5 | |
| ≥pT3a | 67.8 | |
| Pathologic stage pT3ca | 0.032 | |
| <pT3c | 74.6 | |
| ≥pT3c | 60.1 | |
| Pathologic stage pT4aa | 0.005 | |
| <pT4a | 74.4 | |
| ≥pT4a | 48.0 |
aClassification according to the standard of American Joint Committee on Cancer staging system.
Fig. 1Biochemical recurrence-free survival according to tumor density, using a cutoff of 10% (p=0.007).
Multivariate analysis of the risk factors for biochemical recurrence
| p-value | HR | 95% CI for HR | |
|---|---|---|---|
| Surgical margin invasion | 0.000 | 3.066 | 1.636~5.745 |
| Tumor-prostate ratio ≥10% | 0.026 | 1.991 | 1.087~3.645 |
HR: hazard ratio, CI: confidence interval.
Fig. 2A schematic illustrating a hypothetical scenario in which one patient has a larger prostate than the other, with identical tumor volumes. The patient with the smaller prostate will likely have a worse prognosis.